Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 1, 2022 | Post-IPO Debt | $450M | 1 | Royalty Pharma | — | Detail |
Jul 21, 2021 | Post-IPO Equity | $316.25M | — | — | — | Detail |
Jul 16, 2020 | Post-IPO Equity | $201.30M | — | — | — | Detail |
Feb 20, 2014 | Post-IPO Equity | $37.40M | — | — | — | Detail |
Jun 19, 2012 | Post-IPO Equity | $42.50M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Royalty Pharma | Yes | Post-IPO Debt |
Deepfield | Yes | Post-IPO Equity |
Vulcan | Yes | Series E |
Federated Kaufmann Fund | — | Post-IPO Equity |
Red Abbey Venture Partners | — | Post-IPO Equity |